首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Partial agonist effect of the platelet-activating factor receptor antagonists WEB 2086 and WEB 2170 in the rat perfused heart.
【2h】

Partial agonist effect of the platelet-activating factor receptor antagonists WEB 2086 and WEB 2170 in the rat perfused heart.

机译:血小板活化因子受体拮抗剂WEB 2086和WEB 2170在大鼠灌注心脏中的部分激动作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. WEB 2086 and WEB 2170 are potent platelet-activating factor (PAF) receptor antagonists and have been used widely as pharmacological tools to investigate the actions of PAF in a variety of biological systems. 2. Low concentrations of WEB 2086 and WEB 2170 blocked the vasoconstrictor action of PAF in the rat perfused heart. In this study, we observed that moderate concentrations of WEB 2086 and WEB 2170 increased the perfusion pressure in rat isolated hearts under constant flow perfusion. The vasoconstrictor actions of WEB 2086 and WEB 2170 were not observed with a structurally different PAF receptor antagonist, FR-900452. 3. To determine whether this vasoconstrictor action of WEB 2086 involved non-specific effects or was via the activation of PAF receptors, hearts were pretreated with 1000 pmol PAF or 50 microM FR-900452. These pretreatments attenuated the vasoconstrictor action of 1 microM WEB 2086, suggesting that the action of WEB 2086 may be mediated via PAF receptors. Pretreatment with the leukotriene receptor antagonist (L-649,923, 5 microM) and the leukotriene synthesis inhibitor (MK-886, 10 microM) that are known to block the vasoconstrictor action of PAF receptor activation also attenuated the vasoconstrictor action of WEB 2086. Pretreatment with PAF or MK-886 attenuated the vasoconstrictor action of 0.5 microM WEB 2170. 4. When PAF receptors were activated by PAF in the perfused heart, significant amounts of leukotriene C4 and leukotriene C4/D4/E4 were detected in the coronary effluent. However, no significant amount of these leukotrienes was detected in the coronary effluent when hearts were perfused with 1 microM WEB 2086 or 0.5 microM WEB 2170.(ABSTRACT TRUNCATED AT 250 WORDS)
机译:1. WEB 2086和WEB 2170是有效的血小板活化因子(PAF)受体拮抗剂,已广泛用作研究PAF在多种生物系统中作用的药理学工具。 2.低浓度的WEB 2086和WEB 2170阻断了大鼠灌注心脏中PAF的血管收缩作用。在这项研究中,我们观察到中等浓度的WEB 2086和WEB 2170在恒定血流灌注下增加了离体大鼠心脏的灌注压力。使用结构上不同的PAF受体拮抗剂FR-900452,未观察到WEB 2086和WEB 2170的血管收缩作用。 3.为了确定WEB 2086的这种血管收缩作用是否涉及非特异性作用,还是通过激活PAF受体,用1000 pmol PAF或50 microM FR-900452预处理心脏。这些预处理减弱了1 microM WEB 2086的血管收缩作用,表明WEB 2086的作用可能是通过PAF受体介导的。用已知阻断PAF受体激活的血管收缩作用的白三烯受体拮抗剂(L-649,923,5 microM)和白三烯合成抑制剂(MK-886,10 microM)进行预处理也减弱了WEB 2086的血管收缩作用。 PAF或MK-886减弱了0.5 microM WEB 2170的血管收缩作用。4.当PAF受体在灌注心脏中被PAF激活时,在冠状流出物中检测到大量白三烯C4和白三烯C4 / D4 / E4。但是,当用1 microM WEB 2086或0.5 microM WEB 2170灌注心脏时,在冠状流出物中未检测到大量的白三烯。(摘要截断为250字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号